. "http://www.isvav.cz/projectDetail.do?rowId=NT13899"^^ . . "Myelodysplastic syndrome; Chronic myeloid leukemia; mutation; Next Generation Sequencing; Individual Therapy"@en . . "THE NEXT GENERATION SEQUENCING AS A TOOL OF PERSONAL MEDICINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOID LEUKEMIA."@en . " Next Generation Sequencing" . . . "Myelodysplastic syndrome" . "1"^^ . . "The proposed project applies Next-generation sequencing for ultra-deep mutation detection in genes involved in genome methylation processes (TET2, ASXL1, IDH1 / 2, TP53, EZH2) in patients with myelodysplastic syndrome (MDS). We will determine the relationship between the success of therapy and the gene mutation status in patients receiving the demethylation treatment. In addition, we will study the relationship between quantity of TP53 mutations and treatment failure in patients treated with Lenalidomide. In chronic myeloid leukemia (CML) we would like to determine the predictive value of ultra-deep sequencing of BCR-ABL mutations for resistance development on tyrosine kinase inhibitors. We will also study the association between polymorphisms found in promoter regions of genes belonging to the superfamilies of membrane transporters (ABC and SLC) and response to treatment. This project introduces the possibility of using molecular high-technology as a tool for individualizing therapy of MDS and CML."@en . . "NT13899" . "3"^^ . . "0"^^ . . "3"^^ . " Chronic myeloid leukemia" . "Sekvenov\u00E1n\u00ED nov\u00E9 generace se st\u00E1v\u00E1 st\u00E1le roz\u0161\u00ED\u0159en\u011Bj\u0161\u00ED technologi\u00ED s obrovsk\u00FDm potenci\u00E1lem vy\u0161et\u0159ov\u00E1n\u00ED onkologick\u00FDch onemocn\u011Bn\u00ED. P\u0159edkl\u00E1d\u00E1n\u00FD projekt vyu\u017E\u00EDv\u00E1 tuto technologii k detekci mutac\u00ED v genech, kter\u00E9 se zapojuj\u00ED do procesu metylace genomu (TET2, ASXL1, IDH1/2, TP53 a EZH2) u pacient\u016F s myelodysplastick\u00FDm syndromem (MDS). Budeme zji\u0161\u0165ovat vztah mezi \u00FAsp\u011B\u0161nost\u00ED demetyla\u010Dn\u00ED l\u00E9\u010Dby a muta\u010Dn\u00EDm stavem gen\u016F. Nav\u00EDc budeme studovat souvislost mezi kvantitou mutace TP53 a efektem l\u00E9\u010Dby u pacient\u016F l\u00E9\u010Den\u00FDch lenalidomidem. D\u00E1le budeme zji\u0161\u0165ovat prediktivn\u00ED dopady ultracitliv\u00E9 detekce mutac\u00ED v kin\u00E1zov\u00E9 dom\u00E9n\u011B BCR-ABL s rozvojem rezistence na l\u00E9\u010Dbu imatinibem, nilotinibem a dasatinibem u pacient\u016F s chronickou myeloidn\u00ED leuk\u00E9mi\u00ED (CML). Zam\u011B\u0159\u00EDme se tak\u00E9 na asociace mezi polymorfismy v promotorov\u00FDch oblastech gen\u016F transportn\u00EDch p\u0159ena\u0161e\u010D\u016F (ABC a SLC) a odpov\u011Bd\u00ED na l\u00E9\u010Dbu. Touto studi\u00ED bychom cht\u011Bli modelov\u011B p\u0159edstavit mo\u017Enost vyu\u017Eit\u00ED molekul\u00E1rn\u00ED high-technologie jako n\u00E1stroje pro individualizaci terapie MDS a CML." . "0"^^ . . . "SEKVENOV\u00C1N\u00CD NOV\u00C9 GENERACE JAKO N\u00C1STROJ PERSON\u00C1LN\u00CD MEDIC\u00CDNY U PACIENT\u016E S MYELODYSPLASTICK\u00DDM SYNDROMEM A CHRONICKOU MYELOIDN\u00CD LEUK\u00C9MI\u00CD." . "2012-04-01+02:00"^^ . . "2014-03-21+01:00"^^ . . . "2015-01-22+01:00"^^ . "2015-12-31+01:00"^^ . . . . " mutation" .